PURPOSE: To evaluate the outcome of radiotherapy (RT) versus radiochemotherapy (RT-CHT) in patients with locally advanced (stage III) inoperable adenocarcinoma of the lung. PATIENTS AND METHODS: 146 patients with these characteristics were among 600 patients enrolled into five prospective trials and were treated with either hyperfractionated (Hfx) RT (64.8 and 69.6 Gy using 1.2 Gy bid) alone (n = 33) or with Hfx RT (64.8 and 69.6 Gy using 1.2 Gy bid and 67.6 Gy using 1.3 Gy bid) and concurrent carboplatin-etoposide or paclitaxel-carboplatin (n = 113). RESULTS: The median times and 5-year overall survival (OS), local progression-free survival (LPFS) and the distant metastasis-free survival (DMFS) rates for all 146 patients were 17, 20 and 20 months, respectively, and 15, 26 and 33, respectively. RT-CHT was superior to RT alone in terms of both OS (MST 19 vs. 12 months, respectively, 5-year OS 18 vs. 6 %, respectively; p = 0.003) and LPFS (MTLP 21 vs. 15 months, respectively, 5-year LPFS 28 vs. 0 %; p = 0.06), but not the DMFS (p = 0.43). In all 146 patients, the most frequent acute high-grade toxicity was esophageal, bronchopulmonary and hematological (each 12 %), while the most frequent late high-grade toxicity was bronchopulmonary (4 %) and esophageal (3 %). RT-CHT caused significantly more frequent acute high-grade (>3) esophageal (15 %), and hematological (15 %), while late high-grade toxicity was similar between RT and RT-CHT groups of patients. CONCLUSION: RT-CHT achieved excellent results (MST 19 months, 5-year survival 18 %) in this patient population accompanied with low toxicity, comparing favorably to results of other similar studies.
PURPOSE: To evaluate the outcome of radiotherapy (RT) versus radiochemotherapy (RT-CHT) in patients with locally advanced (stage III) inoperable adenocarcinoma of the lung. PATIENTS AND METHODS: 146 patients with these characteristics were among 600 patients enrolled into five prospective trials and were treated with either hyperfractionated (Hfx) RT (64.8 and 69.6 Gy using 1.2 Gy bid) alone (n = 33) or with Hfx RT (64.8 and 69.6 Gy using 1.2 Gy bid and 67.6 Gy using 1.3 Gy bid) and concurrent carboplatin-etoposide or paclitaxel-carboplatin (n = 113). RESULTS: The median times and 5-year overall survival (OS), local progression-free survival (LPFS) and the distant metastasis-free survival (DMFS) rates for all 146 patients were 17, 20 and 20 months, respectively, and 15, 26 and 33, respectively. RT-CHT was superior to RT alone in terms of both OS (MST 19 vs. 12 months, respectively, 5-year OS 18 vs. 6 %, respectively; p = 0.003) and LPFS (MTLP 21 vs. 15 months, respectively, 5-year LPFS 28 vs. 0 %; p = 0.06), but not the DMFS (p = 0.43). In all 146 patients, the most frequent acute high-grade toxicity was esophageal, bronchopulmonary and hematological (each 12 %), while the most frequent late high-grade toxicity was bronchopulmonary (4 %) and esophageal (3 %). RT-CHT caused significantly more frequent acute high-grade (>3) esophageal (15 %), and hematological (15 %), while late high-grade toxicity was similar between RT and RT-CHT groups of patients. CONCLUSION: RT-CHT achieved excellent results (MST 19 months, 5-year survival 18 %) in this patient population accompanied with low toxicity, comparing favorably to results of other similar studies.
Authors: Zhongxing Liao; Ritsuko Komaki; Craig Stevens; Jason Kelly; Frank Fossella; Jin S Lee; Pamela Allen; James D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2002-07-01 Impact factor: 7.038
Authors: M Stuschke; W Eberhardt; C Pöttgen; G Stamatis; H Wilke; G Stüben; F Stöblen; H H Wilhelm; H Menker; H Teschler; R D Müller; V Budach; S Seeber; H Sack Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: M Werner-Wasik; C Scott; J D Cox; W T Sause; R W Byhardt; S Asbell; A Russell; R Komaki; J S Lee Journal: Int J Radiat Oncol Biol Phys Date: 2000-12-01 Impact factor: 7.038
Authors: Steven E Schild; Philip J Stella; Susan M Geyer; James A Bonner; Randolph S Marks; William L McGinnis; Steven P Goetz; Steven A Kuross; James A Mailliard; John W Kugler; Paul L Schaefer; James R Jett Journal: Int J Radiat Oncol Biol Phys Date: 2002-10-01 Impact factor: 7.038
Authors: A H Russell; T E Pajak; H M Selim; J C Paradelo; K Murray; P Bansal; J D Cooper; S Silverman; J A Clement Journal: Int J Radiat Oncol Biol Phys Date: 1991-08 Impact factor: 7.038
Authors: M A Socinski; C Zhang; J E Herndon; R O Dillman; G Clamon; E Vokes; W Akerley; J Crawford; M C Perry; S L Seagren; M R Green Journal: Ann Oncol Date: 2004-07 Impact factor: 32.976
Authors: R Komaki; C B Scott; R Byhardt; B Emami; S O Asbell; A H Russell; M Roach; M B Parliament; L E Gaspar Journal: Int J Radiat Oncol Biol Phys Date: 1998-09-01 Impact factor: 7.038